Last reviewed · How we verify

NCT02441036

Gene Expression Following Ultherapy® Treatment

Terminated NA Results posted Last updated 20 February 2019
What this trial tests

NA trial testing Ultherapy Treatment in Skin Laxity in 16 participants. Terminated before completion.

Timeline
1 May 2015
Primary endpoint
18 August 2016
18 August 2016

Quick facts

Lead sponsorUlthera, Inc
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposebasic science
Enrollment16
Start date1 May 2015
Primary completion18 August 2016
Estimated completion18 August 2016
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Ulthera, Inc — full company profile →

Who can join

Adults 45 to 70, any sex, with Skin Laxity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Up to 25 subjects will be enrolled and randomized. Randomized subjects will receive one single-side Ulthera® treatment in the pre-auricular region on the face. At each subject's scheduled facelift procedure, resected tissue will be obtained for analysis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Skin Laxity

Currently open trials in the same condition.

Other Ulthera, Inc trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02441036.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing